Open AccessStem Cell and Exosome Therapy in Pulmonary Hypertension
Author(s) -
Seyeon Oh,
JiHye Jung,
Kyung Jin Ahn,
Albert Youngwoo Jang,
Kyunghee Byun,
Phillip C. Yang,
WookJin Chung
Publication year - 2022
Publication title -
korean circulation journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.809
H-Index - 29
eISSN - 1738-5555
pISSN - 1738-5520
DOI - 10.4070/kcj.2021.0191
Subject(s) - medicine , pulmonary hypertension , clinical trial , paracrine signalling , disease , intensive care medicine , epigenetics , bioinformatics , genetic enhancement , stem cell , quality of life (healthcare) , gene , nursing , biochemistry , chemistry , genetics , receptor , biology
Pulmonary hypertension is a rare and progressive illness with a devastating prognosis. Promising research efforts have advanced the understanding and recognition of the pathobiology of pulmonary hypertension. Despite remarkable achievements in terms of improving the survival rate, reducing disease progression, and enhancing quality of life, pulmonary arterial hypertension (PAH) is not completely curable. Therefore, an effective treatment strategy is still needed. Recently, many studies of the underlying molecular mechanisms and technological developments have led to new approaches and paradigms for PAH treatment. Management based on stem cells and related paracrine effects, epigenetic drugs and gene therapies has yielded prospective results for PAH treatment in preclinical research. Further trials are ongoing to optimize these important insights into clinical circumstances.